Home
|
About us
|
Contact us
About AWMSG
All Wales Medicines Strategy Group (AWMSG)
New Medicines Group (NMG)
All Wales Prescribing Advisory Group (AWPAG)
Meetings
Appraisals
Appraisal information
Patients/carers/patient organisations
Healthcare professionals
Pharmaceutical industry
Search and reports
Search and browse
Reports
Medicines management
About
Forthcoming work programme
National prescribing indicators
Clinical effectiveness prescribing programme
Appraisal monitoring
In-patient medication administration record
Patient information leaflets
Library
cabozantinib (Cometriq®)
Reference No. 577
Publication date:
29/01/2015
Appraisal information
cabozantinib (Cometriq®) 20 mg capsule
cabozantinib (Cometriq®) 80 mg capsule
Company:
Swedish Orphan Biovitrum Ltd/TMC Pharma Services Ltd
BNF category:
Malignant disease and immunosupression
NMG meeting date:
19/11/2014
AWMSG meeting date:
17/12/2014
Submission Type:
Full Submission
Status:
Recommended
Advice No:
4014
Ministerial ratification:
28/01/2015
Current Progress
Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification
AWMSG advice
Cabozantinib (Cometriq®) is recommended as an option for use within NHS Wales for the treatment of adult patients with progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma. For patients in whom Rearranged during Transfection (RET) mutation status is not known or is negative, a possible lower benefit should be taken into account before individual treatment decision.
Final Appraisal Recommendation (FAR)
Download
Cabozantinib (Cometriq) 577 FAR
AWMSG Secretariat Appraisal Report (ASAR)
Download
Cabozantinib (Cometriq) 577 ASAR
Clinical Expert (CE) Summary
Download
Cabozantinib (Cometriq) 577 CE Summary
